logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10138479 B1

PDFFull Text
Date of Patent:
Nov. 27, 2018

Filed:

May. 23, 2013

Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer

Applicants:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);

Inventors:

Alec Kimmelman, Weston, MA (US);

Jaekyoung Son, Somerville, MA (US);

Lewis Cantley, Cambridge, MA (US);

Costas A. Lyssiotis, Jamaica Plain, MA (US);

Assignees:

Dana-Farber Cancer Institute, Inc., Boston, MA (US);

Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);

Attorney:

Fish & Richardson P.C.

Primary Examiner:

Richard A Schnizer

Int. Cl.
CPC ...
C12N 15/113 (2010.01); C12Q 1/32 (2006.01); C12Q 1/34 (2006.01); A61K 31/04 (2006.01); A61K 31/194 (2006.01); A61K 31/4196 (2006.01); A61K 31/7068 (2006.01); C07K 16/00 (2006.01); C12Q 1/52 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/04 (2013.01); A61K 31/194 (2013.01); A61K 31/4196 (2013.01); A61K 31/7068 (2013.01); C07K 16/00 (2013.01); C12N 15/1135 (2013.01); C12N 15/1137 (2013.01); C12Q 1/34 (2013.01); C12Q 1/52 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/16 (2013.01); C12N 2310/531 (2013.01); G01N 2333/902 (2013.01); G01N 2333/914 (2013.01); G01N 2333/91188 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.

Find Patent Forward Citations

Quick Actions:

Kimmelman, Alec. (2018). Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer (U.S. Patent No. 10138479). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10138479

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…